Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma

Background: Despite improvements in surgical methodologies and perioperative chemo- and radiotherapy, the prognosis for patients with esophageal and gastric cancer remains poor. Hence, there is a great need to identify complementary biomarkers for improved treatment stratification. Tumor-infiltratin...

Full description

Bibliographic Details
Main Authors: Martin Jeremiasen, David Borg, Charlotta Hedner, Maria Svensson, Björn Nodin, Karin Leandersson, Jan Johansson, Karin Jirström
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.534761/full
id doaj-bb05d56b6c934735a9d51b3acf1c2c2a
record_format Article
spelling doaj-bb05d56b6c934735a9d51b3acf1c2c2a2020-11-25T03:52:47ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-10-011010.3389/fonc.2020.534761534761Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal AdenocarcinomaMartin Jeremiasen0Martin Jeremiasen1David Borg2David Borg3Charlotta Hedner4Maria Svensson5Björn Nodin6Karin Leandersson7Jan Johansson8Jan Johansson9Karin Jirström10Department of Clinical Sciences Lund, Surgery, Lund University, Lund, SwedenSkåne University Hospital, Lund, SwedenSkåne University Hospital, Lund, SwedenDepartment of Clinical Sciences Lund, Oncology and Therapeutic Pathology, Lund University, Lund, SwedenDepartment of Clinical Sciences Lund, Oncology and Therapeutic Pathology, Lund University, Lund, SwedenDepartment of Clinical Sciences Lund, Oncology and Therapeutic Pathology, Lund University, Lund, SwedenDepartment of Clinical Sciences Lund, Oncology and Therapeutic Pathology, Lund University, Lund, SwedenCancer Immunology, Department of Translational Medicine, Lund University, Malmö, SwedenDepartment of Clinical Sciences Lund, Surgery, Lund University, Lund, SwedenSkåne University Hospital, Lund, SwedenDepartment of Clinical Sciences Lund, Oncology and Therapeutic Pathology, Lund University, Lund, SwedenBackground: Despite improvements in surgical methodologies and perioperative chemo- and radiotherapy, the prognosis for patients with esophageal and gastric cancer remains poor. Hence, there is a great need to identify complementary biomarkers for improved treatment stratification. Tumor-infiltrating immune cells have been shown to impact on outcome in many types of cancer, including gastroesophageal cancer. The aim of this present study was to examine the prognostic value of tumor-infiltrating macrophages in gastroesophageal adenocarcinoma.Methods: The density of CD68+, CD163+, and MARCO+ macrophages was assessed by immunohistochemistry on tissue microarrays with primary tumors from a consecutive, retrospective cohort of 174 patients with treatment-naïve gastroesophageal adenocarcinoma. Total densities and infiltration in tumor nest (TN) were denoted as none/sparse (0), intermediate (1), or high (2). The impact on overall survival (OS) was examined by Kaplan–Meier analysis, log-rank test, and Cox proportional hazards modeling.Results: Increased infiltration of both CD68+ and CD163+, but not MARCO+, macrophages in TN was significantly associated with a stepwise reduced survival. Median OS for patients with none/sparse, intermediate, and high CD68+ TN infiltration was 4.4, 2.6, and 1.0 years, respectively. Median OS for patients with none/sparse, intermediate, and high CD163+ TN infiltration was 4.4, 2.2, and 1.1 years, respectively. High infiltration of CD68+ macrophages remained an independent prognostic factor in adjusted analysis (hazard ratio = 1.61, 95% confidence interval = 1.02–2.55, and p = 0.041).Conclusion: Infiltration of CD68+ and CD163+, but not MARCO+, macrophages is prognostic for OS in gastroesophageal adenocarcinoma. The relevance of this finding in clinical practice remains to be elucidated.https://www.frontiersin.org/articles/10.3389/fonc.2020.534761/fullesophageal cancergastric cancermacrophagesprognosistreatment naïve
collection DOAJ
language English
format Article
sources DOAJ
author Martin Jeremiasen
Martin Jeremiasen
David Borg
David Borg
Charlotta Hedner
Maria Svensson
Björn Nodin
Karin Leandersson
Jan Johansson
Jan Johansson
Karin Jirström
spellingShingle Martin Jeremiasen
Martin Jeremiasen
David Borg
David Borg
Charlotta Hedner
Maria Svensson
Björn Nodin
Karin Leandersson
Jan Johansson
Jan Johansson
Karin Jirström
Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma
Frontiers in Oncology
esophageal cancer
gastric cancer
macrophages
prognosis
treatment naïve
author_facet Martin Jeremiasen
Martin Jeremiasen
David Borg
David Borg
Charlotta Hedner
Maria Svensson
Björn Nodin
Karin Leandersson
Jan Johansson
Jan Johansson
Karin Jirström
author_sort Martin Jeremiasen
title Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma
title_short Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma
title_full Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma
title_fullStr Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma
title_full_unstemmed Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma
title_sort tumor-associated cd68+, cd163+, and marco+ macrophages as prognostic biomarkers in patients with treatment-naïve gastroesophageal adenocarcinoma
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2020-10-01
description Background: Despite improvements in surgical methodologies and perioperative chemo- and radiotherapy, the prognosis for patients with esophageal and gastric cancer remains poor. Hence, there is a great need to identify complementary biomarkers for improved treatment stratification. Tumor-infiltrating immune cells have been shown to impact on outcome in many types of cancer, including gastroesophageal cancer. The aim of this present study was to examine the prognostic value of tumor-infiltrating macrophages in gastroesophageal adenocarcinoma.Methods: The density of CD68+, CD163+, and MARCO+ macrophages was assessed by immunohistochemistry on tissue microarrays with primary tumors from a consecutive, retrospective cohort of 174 patients with treatment-naïve gastroesophageal adenocarcinoma. Total densities and infiltration in tumor nest (TN) were denoted as none/sparse (0), intermediate (1), or high (2). The impact on overall survival (OS) was examined by Kaplan–Meier analysis, log-rank test, and Cox proportional hazards modeling.Results: Increased infiltration of both CD68+ and CD163+, but not MARCO+, macrophages in TN was significantly associated with a stepwise reduced survival. Median OS for patients with none/sparse, intermediate, and high CD68+ TN infiltration was 4.4, 2.6, and 1.0 years, respectively. Median OS for patients with none/sparse, intermediate, and high CD163+ TN infiltration was 4.4, 2.2, and 1.1 years, respectively. High infiltration of CD68+ macrophages remained an independent prognostic factor in adjusted analysis (hazard ratio = 1.61, 95% confidence interval = 1.02–2.55, and p = 0.041).Conclusion: Infiltration of CD68+ and CD163+, but not MARCO+, macrophages is prognostic for OS in gastroesophageal adenocarcinoma. The relevance of this finding in clinical practice remains to be elucidated.
topic esophageal cancer
gastric cancer
macrophages
prognosis
treatment naïve
url https://www.frontiersin.org/articles/10.3389/fonc.2020.534761/full
work_keys_str_mv AT martinjeremiasen tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma
AT martinjeremiasen tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma
AT davidborg tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma
AT davidborg tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma
AT charlottahedner tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma
AT mariasvensson tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma
AT bjornnodin tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma
AT karinleandersson tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma
AT janjohansson tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma
AT janjohansson tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma
AT karinjirstrom tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma
_version_ 1724481011860897792